Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

Annals of Hematology

Volumn 91, Issue 12, 2012, Pages 1887-1895

  Santamaría, Carlos ^a,k   Ramos, Fernando ^b,j   Puig, Noemi ^a   Barragán, Eva ^c   De Paz, Raquel ^d   Pedro, Carme ^e   Insunza, Andrés ^f   Tormo, Mar ^g   Del Cañizo, Consuelo ^a,k   Diez Campelo, María ^a   Xicoy, Blanca ^h   Salido, Eduardo ⁱ   Del Real, Javier Sánchez ^b   Hernández, Montserrat ^a   Chillón, Carmen ^a   Sanz, Guillermo F ^c   García Sanz, Ramón ^a,k   San Miguel, Jesús F ^a,k   González, Marcos ^a,k  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL DE LEÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^j UNIVERSITY OF LEÓN   (Spain)

^k Centro de Investigacion del Cancer   (Spain)

more..

Author keywords

Molecular prognosis; Myelodysplastic syndrome; Real time PCR; WT1

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; WT1 PROTEIN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; EVI1 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IER3 GENE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; P15 CDKN2B GENE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL; TET2 GENE; TREATMENT FREE SURVIVAL; WT1 GENE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; BLOOD CELLS; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84870994671     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1538-7     Document Type: Article

References (41)

1. Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872-1885
2. Cazzola M, Malcovati L (2005) Myelodysplastic syndromes- coping with ineffective hematopoiesis. N Engl J Med 352:536-538
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French- American-British Cooperative Group. Ann InternMed 103:620-625
4. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302
5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951
6. Cazzola M, Malcovati L (2010) Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin N Am 24:459-468
7. Nimer SD (2008) Myelodysplastic syndromes. Blood 111:4841-4851
8. Greenberg P, Cox C, LeBeauMM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring systemfor evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
9. Malcovati L, Germing U, Kuendgen A, la Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510
10. Bowen DT, Fenaux P, Hellstrom-Lindberg E, de Witte T (2008) Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol 26:1180-1182
11. Nowell PC (1992) Chromosome abnormalities in myelodysplastic syndromes. Semin Oncol 19:25-33
12. Bejar R, Stevenson K, Bdel-Wahab O, Galili N, Nilsson B, Garcia- Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506
13. Delhommeau F, Dupont S, Della VV, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M, Vainchenker W, Bernard OA (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301
14. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24:1094-1096
15. Thol F,Weissinger EM, Krauter J, Wagner K, Damm F,Wichmann M, Gohring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Ganser A, Heuser M (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668-1674
16. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birbaum D, Gelsi-Boyer V, Mozziconacci MJ (2010) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10:401
17. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842
18. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-147
19. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, La-Valle V, Picard F, Viguie F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault- Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M(2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114:3285-3291
20. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP (2002) Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100:3553-3560
21. Mills KI, Kohlmann A, Williams PM, Wieczorek L, Liu WM, Li R, Wei W, Bowen DT, Loeffler H, Hernandez JM, Hofmann WK, Haferlach T (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063-1072
22. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL (2009) Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 114:4847-4858
23. Wang YY, Cen JN, He J, Shen HJ, Liu DD, Yao L, Qi XF, Chen ZX (2009) Accelerated cellular senescence in myelodysplastic syndrome. Exp Hematol 37:1310-1317
24. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, Campbell LJ, Wang L, Langford CF, Fidler C, Oscier D, Aul C, Wainscoat JS, Boultwood J (2006) Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 108:337-345
25. Pellagatti A, Marafioti T, Paterson JC, Malcovati L, la Porta MG, Jadersten M, Pushkaran B, George TI, Arber DA, Killick S, Giagounidis A, Hellstrom-Lindberg E, Cazzola M, Wainscoat JS, Boultwood J (2009) Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 146:86-90
26. Santamaria CM, Chillon MC, Garcia-Sanz R, Perez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizan JA, Rodriguez JN, Fernandez-Abellan P, Barez A, Penarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Az-Mediavilla J, San Miguel JF, Gonzalez M (2009) Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 114:148-152
27. Briatore F, Barrera G, Pizzimenti S, Toaldo C, Casa CD, Laurora S, Pettazzoni P, Dianzani MU, Ferrero D (2009) Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol Ther 8:883-889
28. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G (2003) Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 21:1988-1995
29. Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AA, Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado M (2009) Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome. Int J Hematol 89:173-187
30. Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP (2009) Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res 69:7518-7523
31. Metzeler KH, Maharry K, Radmacher MD,Mrozek K, Margeson D, Becker H, Curfman J,HollandKB, Schwind S,Whitman SP,Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD (2011) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381
32. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo YY, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2011) TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 118:3803-3810
33. Albano F, Anelli L, Zagaria A, Coccaro N, Minervini A, Rossi AR, Specchia G (2011) Decreased TET2 gene expression during chronic myeloid leukemia progression. Leuk Res 35:e220-e222
34. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DE (1990) An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61:1257-1269
35. Saglio G, Carturan S, Grillo S, Capella S, Arruga F, Defilippi I, Rosso V, Rauco M, Marina LA, Cilloni D (2005) WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias. Hematology 10(Suppl 1):76-78
36. Barragán E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P, Collado R, Sayas MJ, Sanz MA (2004) Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89:926-933
37. Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK, Edelmann J, Thiery J, Niederwieser D (2011) Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25:498-505
38. Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, Karasuno T, Mitani K, Kodera Y, Yamagami T, Koga D (2010) Prognostic potential of detection ofWT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma 51:1855-1861
39. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Fuchigami K, Tomonaga M, Toyama K, Aozasa K, Kishimoto T, Sugiyama H (1999) The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13:393-399
40. Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva OA, Oka Y, Oji Y, Sugiyama H, Ogata K (2010) Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res 34:986-990
41. Lugthart S, Drunen EV, Norden YV, Hoven AV, Erpelinck CA, Valk PJ, Beverloo HB, Lowenberg B, Delwel R (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111:4329-4337